Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of apixaban vs enoxaparin for prevention of venous thromboembolism in acutely ill medical patients
2006-003674-96Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apixaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary composite endpoint of total VTE and VTE-related death. Started May 2007; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2006-003674-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003674-96.